APCCC 2022 | PSMA PET vs conventional imaging

Silke Gillessen, MD, PhD, University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses instances in which a consensus was not reached on questions relating to clinical cases during the Advanced Prostate Cancer Consensus Conference (APCCC). Prof. Gillessen specifically discusses the lack of consensus relating to metastatic hormone-sensitive prostate cancer (mHSPC) treatment which arises from the use of novel imaging rather than conventional imaging techniques. This interview took place at the APCCC 2022 conference, held in Lugano, Switzerland.